Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01188668 · ClinicalTrials.gov registry record · Phase 4

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

A Phase 4 study of Pharmacokinetics and Cytochrome P-450 CYP2D6, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
38
Enrollment target
2
Study locations

NCT01188668 is a Phase 4 study of Pharmacokinetics and Cytochrome P-450 CYP2D6 that has completed, run by Pfizer. The registered enrollment target is 38 participants, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (38% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01188668, a Phase 4 study of Pharmacokinetics and Cytochrome P-450 CYP2D6, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
38 participants
Enrollment target
2
Study locations

Study Summary

The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects. This study will also evaluate the safety and tolerability of Desvenlafaxine SR and Aripiprazole when coadministered to healthy adult subjects.

Interventions

  • DRUG Aripiprazole
  • DRUG Aripiprazole + desvenlafaxine succinate sustained release

Study Locations (2)

Florida

  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Miami

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2010-08
Est. Completion 2010-10
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01188668

The ClinicalTrials.gov registry entry for NCT01188668 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (38% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which Aripiprazole is the first listed.

NCT01188668 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01188668 about?

NCT01188668 is a clinical study titled "Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects". The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects. This study will also evaluate the safety and tolerability of Desvenlafaxine SR and Aripiprazole when coad...

What is the current status of trial NCT01188668?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2010-08. Estimated completion is 2010-10.

What conditions does trial NCT01188668 study?

This clinical trial studies the following conditions: Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human.

What interventions are being tested in trial NCT01188668?

The interventions under investigation include: Aripiprazole (DRUG), Aripiprazole + desvenlafaxine succinate sustained release (DRUG).

Who is sponsoring clinical trial NCT01188668?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01188668 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pharmacokinetics

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.